Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy

Journal of Geriatric Oncology

Volumn 5, Issue 2, 2014, Pages 148-155

  Nyrop, Kirsten A ^a   Muss, Hyman B ^a,b   Hackney, Betsy ^a   Cleveland, Rebecca ^a   Altpeter, Mary ^a   Callahan, Leigh F ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase inhibitor; Arthralgia; Physical activity

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE;

AGED; ARTHRALGIA; ARTHRITIS SELF EFFICACY SCALE; ARTICLE; BODY MASS; BREAST CANCER; CANCER SURVIVOR; CLINICAL TRIAL; FATIGUE; FEMALE; GERIATRIC PATIENT; HUMAN; JOINT STIFFNESS; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; VISUAL ANALOG SCALE; WALKING; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; FEASIBILITY STUDY; JOINT CHARACTERISTICS AND FUNCTIONS; PROCEDURES; QUALITY OF LIFE; SELF CARE; SELF CONCEPT; SURVIVOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; ARTHRALGIA; BODY MASS INDEX; BREAST NEOPLASMS; FATIGUE; FEASIBILITY STUDIES; FEMALE; HUMANS; NEOPLASM STAGING; QUALITY OF LIFE; RANGE OF MOTION, ARTICULAR; SELF CARE; SELF EFFICACY; SURVIVORS; TREATMENT OUTCOME; WALKING;

EID: 84896126721     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.12.002     Document Type: Article

References (81)

1. Surveillance Epidemiology and End Results (SEER) Breast cancer: SEER fact sheets. National Cancer Institute [Internet] Available from:. http://seer.cancer.gov/statfacts/html/breast/html.
2. Taylor W.C., Muss H.B. Adjuvant therapy for older women with breast cancer. Cancer J 2010, 16:289-293.
3. Dent S.F., Gaspo R., Kissner M., Prichard K.I. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011, 126:296-310.
4. Witherby S.M., Muss H.B. Special issues related to breast cancer adjuvant therapy in older women. Breast 2005, 14:600-611.
5. Muss H.B. Adjuvant treatment of elderly breast cancer patients. Breast 2007, 16(Suppl. 2):A159-A165.
6. Burstein H.J., Griggs J.J., Prestrud A.A., Temin S. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 6(5):243-246.
7. Wildiers H., Kunkler I., Biganzoli L., Fracheboud J., Vlastos G., Bernard-Marty C., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8(12):1101-1115.
8. Coleman R.E., Bolten W.W., Lansdown M., Dale S., Jackisch C., Merkel D., et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34(3):275-282.
9. Khan Q.J., O'Dea A.P., Sharma P. Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol 2010, (Epub 2010 Aug 24). 10.1155/2010/654348.
10. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007, 14(Suppl. 1):S11-S19.
11. Henry N.L., Giles J.T., Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 2008, 22(15):1401-1408.
12. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
13. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11):1081-1092.
14. Breast International Group (BIG) 1-98 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26):2747-2757.
15. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., et al. A randomized controlled trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349(19):1793-1802.
16. Burstein H.J. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007, 16:223-224.
17. Boonstra A., van Zadelhoff J., Timmer-Bonte A., Ottevanger P.B., Beurskens C.H.G., van Laarhoven H.W.M. Arthralgia during aromatase inhibitor treatment in early breast cancer. Cancer Nurs 2012, 1-8.
18. Crew K.D., Greenlee H., Capodice J., Raptis G., Brafman L., Fuentes D., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25(25):3877-3883.
19. Dizdar O., Ozcakar L., Malas F.U., Harputluoglu H., Bulut N., et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009, 27(30):4955-4960.
20. Friedman C.F., Bruner D., Xie S., Desai K., Stricker C.T., DeMichele A., et al. Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors. J Clin Oncol 2010, 28(15s):9156. (Abstract).
21. Mao J.J., Stricker C., Bruner D., Xie S., Bowman M.A., Farrar J.T., et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009, 115:3631-3639.
22. Oberguggenberger A., Hubalek M., Sztankay M., Meraner V., Beer B., et al. Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 2011, 128(2):553-561.
23. Presant C.A., Bosserman L.Y., et al. Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007, 7(10):775-778.
24. Kanematsu M., Morimoto M., Honda J., Nagao T., Nakagawa M., et al. The time since last menstrual period is important as a clinical predictor of non-steroidal araomatase inhibitor-related arthralgia. BMC Cancer 2011, 10(11):436.
25. Burstein H.J., Winer E.P. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007, 25(25):3797-3799.
26. Donnellan P.P., Douglas S.L., Cameron D.A., Leonard R.C.F. Aromatase inhibitors and arthralgia. J Clin Oncol 2001, 19(10):2767.
27. Singer O., Cigler T., Moore A.B., Levine A.B., Hentel K., et al. Defining aromatase inhibitor musculoskeletal symptom: a prospective study. Arthritis Care Res 2012, 00(0).
28. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011, 126(2):529-537.
29. Partridge A.H., LaFountain A., Mayer E., Taylor B.S., Winer E., Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26(4):556-562.
30. Din O.S., Dodwell D., Wakefield R.J., Coleman R.E. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out?. Breast Cancer Res Treat 2010, 120:525-538.
31. Fontaine C., Meulemans A., Huizing M., Collen C., Kaufman L., DeMey J., et al. Tolerance of adjuvant letrozole outside of clinical trials. Breast 2008, 17(4):376-381.
32. Henry N.L., Azzouz F., Desta Z., Li L., Nguyen A.T., Lemier S., et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012, 30(9):936-942.
33. Din O.S., Dodwell D., Winter M.C., Mori S., Coleman R.E. Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK. Clin Oncol 2011, 23(10):674-680.
34. Briot K., Tubiana-Hulin M., Bastit L., Kloos I., Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010, 120:127-134.
35. Garreau J.R., DeLaMelena T., Walts D., Karamlou K., Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg 2006, 192:496-498.
36. Jones C., Gilmore J., Saleh M., Feinberg B., Kissner M., Simmons S.J. Therapeutic optimization of aromatase inhibitor-associated arthralgia: etiology, onset, resolution, and symptom management in early breast cancer. Community Oncol 2012, 9(3):94-101.
37. Younus J., Kligman L. Management of aromatase inhibitor-induced arthralgia. Curr Oncol 2010, 17(1):87-90.
38. Griffin M. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998, 104(3A):9S-23S. (discussion 41S-2S).
39. Ballard-Barbash R., Friedenreich C.M., Courneya K.S., Siddiqi S.M., McTiernan A., Alfano C.M. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012, 104:815-840.
40. Bicego D., Brown K., Ruddick M., et al. Effects of exercise on quality of life in women living with breast cancer: a systematic review. Breast J 2008, 15(1):45-51.
41. Cramp F., Daniel J. Exercise for the management of cancer-related fatigue in adults (review) 2010, 11:1-31. The Cochrance Collaboration.
42. Duijts S.F.A., Faber M.M., Oldenburg H.S.A., van Beurden M., Aaronson N.K. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors-a meta-analysis. Psycho-Oncology 2011, 20:115-126.
43. McNeely M.L., Campbell K.L., Rowe B.H., Klassen T.P., Mackey J.R., Courneya K.S. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 2006, 175(1):34-41.
44. Schmitz K.H., Holtzman J., Courneya K.S., Masse L.C., Duval S., Kane R. Controlled physical activity trials in cancer survivors: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(7):1588-1595.
45. Speck R.M., Courneya K.S., Masse L.C., Duval S., Schmitz K.H. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2010, 4:87-100.
46. Fong D.Y.T., Ho J.W.C., Hui B.P.H., Lee A.M., Macfarlane D.J., et al. Physical activity for cancer survivors: meta-analysis of randomized controlled trials. BMJ 2012, 344:e70.
47. Schmitz K.H., Courneya K.S., Matthews C., Demark-Wahnefried W., Galvao D.A., et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010, 42(7):1409-1426.
48. Irwin M.L., George S.M., Matthews C.E. Physical activity and breast cancer: prevention, survival, and mechanisms. Res Dig 2010, 11(3):1-9.
49. Doyle C., Kushi L.H., Byers T., Courneya K.S., et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2006, 56:323-353.
50. Norman G.R., Wyrwich K.W., Patrick D.L. The mathematical relationship among different forms of responsiveness coefficients. Qual Life Res 2007, 16(5):815-822.
51. Foundation Arthritis Walk with ease: your guide to walking for better health, improved fitness and less pain 2010, Arthritis Foundation, Atlanta, GA. third ed.
52. Callahan L.F. Physical activity programs for chronic arthritis. Curr Opin Rheumatol 2009, 21(2):177-182.
53. Allegrante J.P., Kovar P.A., MacKenzie C.R., Peterson M.G., Gutin B. A walking education program for patients with osteoarthritis of the knee: theory and intervention strategies. Health Educ Q 1993, 20(1):63-81.
54. Fransen M., McConnell S. Land-based exercise for osteoarthritis of the knee: a metaanalysis of randomized controlled trials. J Rheumatol 2009, 36(6):1109.
55. Callahan L.F., Shreffler J.H., Altpeter M., Schoster B., Hootman J., Houenou L.O., et al. Evaluation of group and self-directed formats of the Arthritis Foundation's (AF) Walk with Ease (WWE) program. Arthritis Care Res 2011, 63(8):1098-1107.
56. Centers for Disease Control, Prevention Physical activity for everyone guidelines 2011, Department of Health and Human Services, Washington, DC.
57. Lorig K., Stewart A., Ritter P., Gonzalez V., Laurent D., Lynch J. Outcome measures for health education and other health care interventions 1996, Sage Publications, Thousand Oaks, CA.
58. Stewart A.L., Hays R.D., Ware J.E. Health perceptions, energy/fatigue, and health distress measures. Measuring functioning and well-being: the Medical Outcomes Study approach 1992, 143-172. Duke University Press, Durham, NC. A.L. Stewart, J.E. Ware (Eds.).
59. Carlsson A.M. Assessment of chronic pain I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983, 16(1):87-101.
60. Jensen M.P. The validity and reliability of pain measures in adults with cancer. J Pain 2003, 4:2-21.
61. Caraceni A., Brunelli C., Martini C., Zecca E., DeConno F. Cancer pain assessment in clinical trials. J Pain Symptom Manage 2005, 29:507-519.
62. Lorig K., Chastain R.L., Ung E., Shoor S., Holman H.R. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum 1989, 32(1):37-44.
63. Brady T.J. Measures of self-efficacy, helplessness, mastery, and control: the Arthritis Helplessness Index (AHI)/Rheumatology Attitudes Index (RAI), Arthritis Self-Efficacy Scale (ASES), Children's Arthritis Self-Efficacy Scale (CASE), Generalized Self-Efficacy Scale (GSES), Mastery Scale, Multi-Dimensional Health Locus of Control Scale (MHLC), Parent's Arthritis Self-Efficacy Scale (PASE), Rheumatoid Arthritis Self-Efficacy Scale (RASE), and Self-Efficacy Scale (SES). Arthritis Care Res 2003, 49(S5):S147-S164.
64. Cohen J. Statistical power analysis for the behavioral sciences 1988, Erlbaum, Hillsdale, NJ. 2nd ed.
65. Corporation S. Stata statistical software 2005, Stata Corporation, College Station, TX. 9.0 ed.
66. Jovanovic J.L., Hughes D.C., Baum G.P., Carmack C., Greisinger J., Basen-Engquist K. Accelerometry and self-report in sedentary populations. Am J Health Behav 2011, 35(1):71-80.
67. Milton K., Clemes S., Bull F. Can a single question provide an accurate measure of physical activity?. Br J Sports Med 2012, 47(1):44-48.
68. PROMIS National Institutes of Health; [07/15/13] Available from. http://www.nihpromis.org.
69. Basch E., Abernathy A.P., Mullins C.D., Reeve B.B., Smith M.L., Coons S.J., et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012, 1-7.
70. Gaillard S., Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011, 13(2):205.
71. Harrison S., Hayes S.C., Newman B. Level of physical activity and characteristics associated with change following breast cancer diagnosis and treatment. Psycho-Oncology 2009, 18:387-394.
72. Irwin M.L., Crumley D., McTiernan A., Bernstein L., Baumgartner R., Gilliland F.D., et al. Physical activity levels before and after a diagnosis of breast cancer; the Health, Eating, Activity, and Lifestyle (HEAL) Study. Cancer 2003, 97:1746-1757.
73. Eheman C., Henley J., Ballard-Barbash R., Jacobs E.J., Schymura M.J., et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012, 118(9):2338-2366.
74. Emery C.F., Yang H.-C., Frierson G.M., Peterson L.J., Suh S. Determinants of physical activity among women treated for breast cancer in a 5-year longitudinal follow-up investigation. Psycho-Oncology 2009, 18:377-386.
75. Offenbacher A.J., Day R.S., Taylor W.C., Sharma S.V., Sloane R., et al. Exercise among breast and prostate cancer survivors-what are their barriers?. J Cancer Surviv 2011, 5(4):413-419.
76. Irwin M.L., McTiernan A., Bernstein L., Gilliland F.D., Baumgartner R., Ballard-Barbash R. Physical activity levels among breast cancer survivors. Med Sci Sports Exerc 2004, 36(9):1484-1491.
77. Hootman J.M., Watson K.B., Harris C., Barbour K.E. State-specific prevalence of no leisure-time physical activity among adults with and without doctor-diagnosed arthritis-United States, 2009. MMWR 2011, 60(48):1641-1645.
78. Brittain D.R., Gvurcsik N.C., McElroy M., Hillard S.A. General and arthritis-specific barriers to moderate physical activity in women with arthritis. Womens Health Issues 2010, 21(1):57-63.
79. Hootman J.M., Helmick C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006, 54(1):226-229.
80. Greenhalgh T., Robert G., Macfarlane F., Bate P., Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q 2004, 82(4):581-629.
81. Fallowfield L. Quality of life issues in relation to the aromatase inhibitor. J Steroid Biochem Mol Biol 2007, 106:168-172.